A. D’Avino

发表

The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study

A. d’Arminio Monforte, M. Capobianchi, L. Iacoviello, 2013, BMC Infectious Diseases.

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

A. d’Arminio Monforte, V. Vullo, A. Antinori, 2017, PLoS ONE.

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, G. Ippolito, 2013, The Journal of antimicrobial chemotherapy.

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients

M. Prosperi, M. Colafigli, A. Borghetti, 2014, BMC Infectious Diseases.

Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area.

S. Di Giambenedetto, M. Fabbiani, A. D’Avino, 2012, Diagnostic microbiology and infectious disease.

Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults.

A. De Luca, A. Borghetti, B. Rossetti, 2019, The new microbiologica.

Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.

A. Borghetti, S. Di Giambenedetto, D. Moschese, 2018, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir

A. Antinori, A. De Luca, A. Gori, 2017, Antiviral therapy.

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study

Alberto Borghetti, Massimiliano Fabbiani, Roberto Cauda, 2012, BMC Infectious Diseases.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.

N. Ciccarelli, M. Colafigli, A. De Luca, 2015, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

P. Narciso, A. Lazzarin, A. Giacomelli, 2018, The Journal of antimicrobial chemotherapy.

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.

N. Ciccarelli, A. De Luca, A. Borghetti, 2016, The Journal of antimicrobial chemotherapy.

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

G. d’Ettorre, V. Vullo, N. Ciccarelli, 2014, Scandinavian journal of infectious diseases.

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, At

N. Ciccarelli, M. Colafigli, A. De Luca, 2013, The Journal of antimicrobial chemotherapy.

Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study

M. Bassetti, A. Russo, Francesco Sabetta, 2020, Infectious Diseases and Therapy.

Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance

M. Silveri, N. Ciccarelli, M. Colafigli, 2013, BMC Psychology.

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre

N. Ciccarelli, A. De Luca, A. Borghetti, 2014, Journal of the International AIDS Society.

Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure.

M. Colafigli, A. De Luca, A. Borghetti, 2014, The Journal of infection.

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients

M. Colafigli, A. De Luca, A. Borghetti, 2017, Journal of chemotherapy.

The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort

F. Castelli, A. Gori, C. Torti, 2016, BMC Public Health.

Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE)

N. Ciccarelli, M. Colafigli, A. Borghetti, 2016, The Clinical neuropsychologist.

Is it time to re-think the use of etravirine in patients with available genotypic resistance test?

M. Zazzi, A. De Luca, A. Borghetti, 2019, Infectious Diseases.

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients

M. Colafigli, A. De Luca, A. Borghetti, 2017, Journal of chemotherapy.

Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy

G. Fadda, M. Sali, N. G. Silveri, 2011, Journal of medical virology.